文献速递乳腺癌

早期乳腺癌新辅助治疗试验中病理学完全缓解的替代终点价值:优势、劣势与误读的批判性分析

Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations.
PubMed 文献 · JAMA Oncol · 2022-01-01

本文批判性分析早期乳腺癌新辅助随机临床试验中病理学完全缓解(pCR)作为替代终点的价值,指出pCR在患者水平与生存相关,但在试验水平与生存改善关联差;讨论了替代终点如联合病理反应与无事件生存数据、循环肿瘤DNA(ctDNA)的潜力;结论认为现有证据不支持pCR单独作为可靠的监管替代终点,需紧急测试更稳健替代终点的试验水平替代价值。

要点

  • pCR在患者水平与生存显著相关,但试验水平上pCR率改善与生存关联差。
  • 监管机构支持pCR作为加速审批的替代终点,但现有证据不支持其单独使用。
  • 联合终点(病理反应+无事件生存)或ctDNA等替代终点可能克服pCR局限。

核心结论

  • 现有证据不支持pCR单独作为乳腺癌监管新辅助随机临床试验中的可靠替代终点。
  • 需紧急测试可能更稳健的替代终点在试验水平的替代价值。

研究设计与样本

  • 本文为对早期乳腺癌新辅助随机临床试验中pCR替代终点价值的批判性分析。

主要发现

  • pCR与患者生存的关联仅在患者水平得到证实,即达到pCR的患者生存显著优于未达到者。
  • 在试验水平,pCR率改善程度与报告的生存之间关联差。
  • 联合分析病理反应与无事件生存数据的联合终点或ctDNA评估等替代终点,可在快速获取有效疗法与可靠评估临床获益之间提供合理权衡。

临床怎么用

  • 监管机构在早期乳腺癌新辅助随机临床试验的新药加速审批中支持pCR作为长期临床结局的替代终点。
  • 作者认为现有证据不支持pCR单独作为可靠的监管替代终点。
  • 作者认为需紧急测试可能更稳健替代终点的试验水平替代价值。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The pathologic complete response (pCR) is supported by regulatory agencies as a surrogate end point for long-term patients' clinical outcomes in the accelerated approval process of new drugs tested in neoadjuvant randomized clinical trials (RCTs) for early breast cancer (BC). However, a meaningful association between pCR and patients' survival has been proven only at the patient level (ie, significantly better survival of patients who achieved pCR compared with those who did not), but not at trial level (ie, poor association between degree of improvement in pCR rate and survival reported across trials). OBSERVATIONS: We critically discuss the potential reasons of such discrepancy between pCR surrogacy value at the patient and trial level, as well as the relevant implications for both clinical research and drug regulatory policy. We also describe alternative surrogate end points, including combined end points that jointly analyzed pathological response and event-free survival data, or the assessment of circulating tumor DNA (ctDNA). Such proposed surrogate end points could overcome limits of pCR and provide a reasonable trade-off between the 2 conflicting needs to have access to effective therapies rapidly, and to reliably assess patients' clinical benefit. CONCLUSIONS AND RELEVANCE: Using surrogate end points to grant drug approvals is justified only when they can provide accurate prediction of a drug's effect on the long-term patient outcomes. Evidence currently available does not support pCR used alone as a reliable surrogate end point in regulatory neoadjuvant RCTs for BC. The surrogacy value at trial level of potentially more robust surrogate end points needs to be urgently tested.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Conforti F, Pala L, Bagnardi V, et al. Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations. JAMA Oncol. 2022. PMID: 36201176. doi:10.1001/jamaoncol.2022.3755

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。